李氏大藥廠(00950.HK):聯營在中國進行的持續葡萄糖監測系統臨牀研究成功招募首名受試者
格隆匯8月5日丨李氏大藥廠(00950.HK)公佈,於2021年8月3日,集團的聯營公司普樂(廣州)藥業有限公司在中國進行的持續葡萄糖監測(CGM)系統臨牀研究成功招募首名受試者。
有關研究為一項隨機、多中心、並行組別介入性醫療儀器臨牀試驗,旨在探討糖尿病患者家用(包括面診時段)CGM系統的效能及安全性。有關測試計劃在中港兩地招募合共144名受試者。參與該研究的中心包括香港威爾斯親王醫院以及中國中山大學附屬第一醫院及中山大學孫逸仙紀念醫院。患者將分為上臂及下腹組別,分別在上臂或下腹設置CGM感應器。招募工作預計將於2022年第一季完成。
該CGM系統乃由普樂藥業有限公司自EyeSense AG引進,為糖尿病領域奠下重要里程碑。該儀器既創新,亦非常準確,建基於先進光學感應技術,初步患者研究數據甚為理想。有關儀器準確、可靠、壽命長,讓患者大大改善病情管理,同時壓低成本及提高舒適度。EyeSense的技術可望顯著擴大CGM市場,增加CGM在糖尿病患者中的普及性。廣州普樂的廣州南沙生產基地已投入生產該CGM系統。該醫療儀器乃首個於中國通過創新醫療器械審批的CGM系統。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.